Serum MicroRNA profiles in chronic hepatitis C Egyptian patients before and after combined sofosbuvir and daclatasvir treatment
Abstract Background MicroRNAs (miR) are small sequence of nucleotides that can affect multiple genes involved in the hepatitis C virus (HCV) life cycle and disease development. The purpose of the present study was to investigate the clinical significance of serum microRNA profiles in a cohort of Egy...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2024-01-01
|
| Series: | BMC Infectious Diseases |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12879-023-08016-2 |
| _version_ | 1827382387597639680 |
|---|---|
| author | Wafaa M. Ezzat Khalda S. Amr Salwa Tawfeek Hassan Elbatae Eman A. Bayomi Ahmed Heiba Yasser Elhosary |
| author_facet | Wafaa M. Ezzat Khalda S. Amr Salwa Tawfeek Hassan Elbatae Eman A. Bayomi Ahmed Heiba Yasser Elhosary |
| author_sort | Wafaa M. Ezzat |
| collection | DOAJ |
| description | Abstract Background MicroRNAs (miR) are small sequence of nucleotides that can affect multiple genes involved in the hepatitis C virus (HCV) life cycle and disease development. The purpose of the present study was to investigate the clinical significance of serum microRNA profiles in a cohort of Egyptian patients with chronic HCV infection before and after combined sofosbuvir and daclatasvir treatment, as well as to gain a better understanding of the exact interaction mechanism in HCV transcriptional activity via differentially expressed miRNAs. For 12 weeks, 50 patients were eligible for and received sofosbuvir (400 mg daily) and daclatasvir (60 mg daily) treatment. Each patient’s blood was obtained twice: once before therapy began and again three months afterwards. Results The current study found that serum levels of circulating miR-122, miR-221, miR-23a, miR-125, miR-217, miR-224, and miR-181a were high in HCV pre-treatment patients, but after 12 weeks of direct-acting antiviral (DAAs) treatment, there was a statistically significant reduction in expression levels of miR-122, miR-221, miR-23a, miR-125, miR-217, and miR-224 (p < 0.001). There is no statistical significance for miR-181a. Conclusion The key differentially expressed microRNAs before and after the direct-acting antiviral (DAA) regimen were connected to the dynamics of chronic HCV infection, suggesting their potential as predictive biomarkers for HCV clearance after sofosbuvir and daclatasvir therapy. |
| first_indexed | 2024-03-08T14:18:49Z |
| format | Article |
| id | doaj.art-15a60f3433c846ae9ee3a90057d72c63 |
| institution | Directory Open Access Journal |
| issn | 1471-2334 |
| language | English |
| last_indexed | 2024-03-08T14:18:49Z |
| publishDate | 2024-01-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Infectious Diseases |
| spelling | doaj.art-15a60f3433c846ae9ee3a90057d72c632024-01-14T12:13:12ZengBMCBMC Infectious Diseases1471-23342024-01-012411810.1186/s12879-023-08016-2Serum MicroRNA profiles in chronic hepatitis C Egyptian patients before and after combined sofosbuvir and daclatasvir treatmentWafaa M. Ezzat0Khalda S. Amr1Salwa Tawfeek2Hassan Elbatae3Eman A. Bayomi4Ahmed Heiba5Yasser Elhosary6Internal Medicine Department, National Research CentreMedical Molecular Genetics Department, National Research CentreInternal Medicine Department, National Research CentreTropical Medicine Department, Kafr Elsheikh UniversityMedical Molecular Genetics Department, National Research CentreInternal Medicine Department, National Research CentreInternal Medicine Department, National Research CentreAbstract Background MicroRNAs (miR) are small sequence of nucleotides that can affect multiple genes involved in the hepatitis C virus (HCV) life cycle and disease development. The purpose of the present study was to investigate the clinical significance of serum microRNA profiles in a cohort of Egyptian patients with chronic HCV infection before and after combined sofosbuvir and daclatasvir treatment, as well as to gain a better understanding of the exact interaction mechanism in HCV transcriptional activity via differentially expressed miRNAs. For 12 weeks, 50 patients were eligible for and received sofosbuvir (400 mg daily) and daclatasvir (60 mg daily) treatment. Each patient’s blood was obtained twice: once before therapy began and again three months afterwards. Results The current study found that serum levels of circulating miR-122, miR-221, miR-23a, miR-125, miR-217, miR-224, and miR-181a were high in HCV pre-treatment patients, but after 12 weeks of direct-acting antiviral (DAAs) treatment, there was a statistically significant reduction in expression levels of miR-122, miR-221, miR-23a, miR-125, miR-217, and miR-224 (p < 0.001). There is no statistical significance for miR-181a. Conclusion The key differentially expressed microRNAs before and after the direct-acting antiviral (DAA) regimen were connected to the dynamics of chronic HCV infection, suggesting their potential as predictive biomarkers for HCV clearance after sofosbuvir and daclatasvir therapy.https://doi.org/10.1186/s12879-023-08016-2HCVmicroRNAsSofosbuvirDaclatasvirEgypt |
| spellingShingle | Wafaa M. Ezzat Khalda S. Amr Salwa Tawfeek Hassan Elbatae Eman A. Bayomi Ahmed Heiba Yasser Elhosary Serum MicroRNA profiles in chronic hepatitis C Egyptian patients before and after combined sofosbuvir and daclatasvir treatment BMC Infectious Diseases HCV microRNAs Sofosbuvir Daclatasvir Egypt |
| title | Serum MicroRNA profiles in chronic hepatitis C Egyptian patients before and after combined sofosbuvir and daclatasvir treatment |
| title_full | Serum MicroRNA profiles in chronic hepatitis C Egyptian patients before and after combined sofosbuvir and daclatasvir treatment |
| title_fullStr | Serum MicroRNA profiles in chronic hepatitis C Egyptian patients before and after combined sofosbuvir and daclatasvir treatment |
| title_full_unstemmed | Serum MicroRNA profiles in chronic hepatitis C Egyptian patients before and after combined sofosbuvir and daclatasvir treatment |
| title_short | Serum MicroRNA profiles in chronic hepatitis C Egyptian patients before and after combined sofosbuvir and daclatasvir treatment |
| title_sort | serum microrna profiles in chronic hepatitis c egyptian patients before and after combined sofosbuvir and daclatasvir treatment |
| topic | HCV microRNAs Sofosbuvir Daclatasvir Egypt |
| url | https://doi.org/10.1186/s12879-023-08016-2 |
| work_keys_str_mv | AT wafaamezzat serummicrornaprofilesinchronichepatitiscegyptianpatientsbeforeandaftercombinedsofosbuviranddaclatasvirtreatment AT khaldasamr serummicrornaprofilesinchronichepatitiscegyptianpatientsbeforeandaftercombinedsofosbuviranddaclatasvirtreatment AT salwatawfeek serummicrornaprofilesinchronichepatitiscegyptianpatientsbeforeandaftercombinedsofosbuviranddaclatasvirtreatment AT hassanelbatae serummicrornaprofilesinchronichepatitiscegyptianpatientsbeforeandaftercombinedsofosbuviranddaclatasvirtreatment AT emanabayomi serummicrornaprofilesinchronichepatitiscegyptianpatientsbeforeandaftercombinedsofosbuviranddaclatasvirtreatment AT ahmedheiba serummicrornaprofilesinchronichepatitiscegyptianpatientsbeforeandaftercombinedsofosbuviranddaclatasvirtreatment AT yasserelhosary serummicrornaprofilesinchronichepatitiscegyptianpatientsbeforeandaftercombinedsofosbuviranddaclatasvirtreatment |